NEW YORK, June 11, 2020 /PRNewswire/ -- BrainStorm
Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of
adult stem cell therapies for neurodegenerative diseases, today
announced Chaim Lebovits, CEO and
Ralph Kern, MD, MHSc, President and
Chief Medical Officer, will present a corporate overview on
Thursday, June 18 at 9:00 am EST, during the Raymond James
Human Health Innovations Conference, a virtual event connecting
institutional investors with company management teams that will be
held June 15-18, 2020.
Mr. Lebovits and Dr. Kern will update conference participants on
the Company's investigational therapeutic, NurOwn®, that is
currently in a fully enrolled phase 3 study for the treatment of
ALS and a phase 2 study for the treatment of progressive multiple
sclerosis. Additionally, they will present an overview of the
Company's financial position and pipeline. After the presentation,
the management team will participate in a question and answer
session with institutional investors.
Mr. Lebovits and Dr. Kern will be joined by David Setboun, PhD,
MBA, Chief Operating Officer, Stacy
Lindborg, PhD, Head of Global Clinical Research, and
Preetam Shah, PhD, MBA, Chief
Financial Officer, for a series of one-on-one meetings, with select
institutional investors arranged by Raymond
James.
Participants can view the presentation via the event link and
those unable to join will have access to an archived link on the
Company's Events and Presentation webpage after the conclusion of
the conference.
EVENT: Raymond James Human Health Innovations
Conference
PRESENTATION: Thursday, June
18th at 9:00 am EST
LINK: https://bit.ly/2YmZf8u
About NurOwn®
NurOwn® (autologous MSC-NTF) cells represent a promising
investigational therapeutic approach to targeting disease pathways
important in neurodegenerative disorders. MSC-NTF cells are
produced from autologous, bone marrow-derived mesenchymal stem
cells (MSCs) that have been expanded and differentiated ex vivo.
MSCs are converted into MSC-NTF cells by growing them under
patented conditions that induce the cells to secrete high levels of
neurotrophic factors. Autologous MSC-NTF cells can effectively
deliver multiple NTFs and immunomodulatory cytokines directly to
the site of damage to elicit a desired biological effect and
ultimately slow or stabilize disease progression. BrainStorm has
fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells
for the treatment of amyotrophic lateral sclerosis (ALS).
BrainStorm also recently received U.S. FDA acceptance to
initiate a Phase 2 open-label multicenter trial in progressive MS
and enrollment began in March 2019.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of
innovative autologous adult stem cell therapeutics for debilitating
neurodegenerative diseases. The Company holds the rights to
clinical development and commercialization of the NurOwn®
technology platform used to produce autologous MSC-NTF cells
through an exclusive, worldwide licensing agreement. Autologous
MSC-NTF cells have received Orphan Drug status designation from
the U.S. Food and Drug Administration (U.S. FDA) and
the European Medicines Agency (EMA) in ALS. BrainStorm
has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056),
investigating repeat-administration of autologous MSC-NTF cells at
six U.S. sites supported by a grant from
the California Institute for Regenerative Medicine (CIRM
CLIN2-0989). The pivotal study is intended to support a filing
for U.S. FDA approval of autologous MSC-NTF cells in ALS.
BrainStorm also recently received U.S. FDA clearance to
initiate a Phase 2 open-label multicenter trial in progressive
Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells
in patients with progressive MS (NCT03799718) started enrollment
in March 2019.
Safe-Harbor Statement
Statements in this announcement other than historical data and
information, including statements regarding future clinical trial
enrollment and data, constitute "forward-looking statements" and
involve risks and uncertainties that could cause BrainStorm
Cell Therapeutics Inc.'s actual results to differ materially
from those stated or implied by such forward-looking statements.
Terms and phrases such as "may", "should", "would", "could",
"will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, BrainStorm's need to
raise additional capital, BrainStorm's ability to continue as a
going concern, regulatory approval of BrainStorm's NurOwn®
treatment candidate, the success of BrainStorm's product
development programs and research, regulatory and personnel issues,
development of a global market for our services, the ability to
secure and maintain research institutions to conduct our clinical
trials, the ability to generate significant revenue, the ability of
BrainStorm's NurOwn® treatment candidate to achieve broad
acceptance as a treatment option for ALS or other neurodegenerative
diseases, BrainStorm's ability to manufacture and commercialize the
NurOwn® treatment candidate, obtaining patents that provide
meaningful protection, competition and market developments,
BrainStorm's ability to protect our intellectual property from
infringement by third parties, heath reform legislation, demand for
our services, currency exchange rates and product liability claims
and litigation,; and other factors detailed in BrainStorm's annual
report on Form 10-K and quarterly reports on Form 10-Q available
at http://www.sec.gov. These factors should be considered
carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the
beliefs, expectations and opinions of management as of the date of
this press release. We do not assume any obligation to update
forward-looking statements to reflect actual results or assumptions
if circumstances or management's beliefs, expectations or opinions
should change, unless otherwise required by law. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.
CONTACTS
Investor Relations:
Preetam
Shah, MBA, PhD
Chief Financial Officer
BrainStorm Cell Therapeutics Inc.
Phone: +1-862-397-1860
pshah@brainstorm-cell.com
Media:
Sean Leous
Westwicke/ICR PR
Phone: +1-646-677-1839
sean.leous@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/brainstorm-to-present-at-the-raymond-james-human-health-innovations-conference-301074370.html
SOURCE Brainstorm Cell Therapeutics Inc